Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control.
Clin Med Insights Endocrinol Diabetes
; 14: 11795514211051698, 2021.
Article
in English
| MEDLINE | ID: covidwho-1511659
ABSTRACT
Dipeptidyl peptidase (DPP)-4 inhibitors are oral anti-diabetic medications that block the activity of the ubiquitous enzyme DPP-4. Inhibition of this enzyme increases the level of circulating active glucagon-like peptide (GLP)-1 secreted from L-cells in the small intestine. GLP-1 increases the glucose level, dependent on insulin secretion from pancreatic ß-cells; it also decreases the abnormally increased level of glucagon, eventually decreasing the blood glucose level in patients with type 2 diabetes. DPP-4 is involved in many physiological processes other than the degradation of GLP-1. Therefore, the inhibition of DPP-4 may have numerous effects beyond glucose control. In this article, we review the pleiotropic effects of DPP-4 inhibitors beyond glucose control, including their strong beneficial effects on the stress induced accelerated senescence of vascular cells, and the possible clinical implications of these effects.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Clin Med Insights Endocrinol Diabetes
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS